Here are key cancer awareness dates and months to note in 2026 across oncology. Explore more about oncology conferences, top trials, and reactions from oncologists: clin.larvol.com #LARVOL #Oncology #CancerCare #CancerAwarenes #BreastCancer #BCSM #LungCancer #LCSM #GICancer #GICSM #GUCancer #GUCSM #Melanoma #Lymphoma #Leukemia #MultipleMyeloma #HEMSM #MMSM #LEUSM #LYMSM #HeadAndNeckCancer #KindneyCancer #ColorectalCancer #BloodCancer

Ahead of @ASCO 2026, we asked leading AI models to identify the GU cancer trials most likely to shape the meeting. We then compared those predictions with engagement on 𝕏 to see where AI and the oncology community aligned—and where they diverged. 👉 Strong alignment at the top Several studies were consistently highlighted across AI models and also generated substantial online attention: ▶️ PROTEUS (644K views) ▶️ KEYNOTE-B15 (137K views) ▶️ RAMPART (104K views) ▶️ TALAPRO-3 (81K views) Together, they reflected strong interest in perioperative and adjuvant treatment strategies across prostate, bladder, and renal cancers. 👉 Where buzz outpaced AI expectations → KEYNOTE-A39 (536K views), driven by continued interest in long-term outcomes for EV pembrolizumab in urothelial cancer → IMvigor011 (259K views), highlighting enthusiasm around ctDNA-guided treatment strategies → POTOMAC (143K views), reflecting attention on immunotherapy in non–muscle-invasive bladder cancer 👉 Themes that resonated across AI and the community ▶️ Perioperative treatment intensification remained a major focus in GU cancers ▶️ Biomarker-driven strategies continued to attract attention, particularly in prostate and bladder cancer ▶️ Long-term follow-up from practice-changing studies generated significant interest ▶️ Adjuvant and minimal residual disease (MRD)/ctDNA-guided approaches remain key areas of development 👉 Where AI and the community diverged AI models tended to prioritize trials with clear practice-changing potential and strong mechanistic rationale, while the community also gravitated toward mature follow-up data, ctDNA-guided studies, and datasets with immediate clinical relevance. Which GU trial from ASCO 2026 generated the most discussion in your network? Explore more insights and conference data from #ASCO26 👉 clin.larvol.com/conference/a… #LARVOL #ASCO2026 #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #ClinicalOncology #GUOncology #GUCancer #GUCSM #GenitourinaryCancer | @DrChoueiri | @neerajaiims | @AndreaNecchi | @UroDocAsh | @nataliagandur

Could AI anticipate the biggest GU cancer readouts from @ASCO 2026? Before the meeting, we asked leading AI models to forecast outcomes for key GU cancer trials and compared those predictions with the results presented at ASCO 2026. Overall accuracy: ➡️ Median survival: R² = 0.97 (n=4) ➡️ Hazard ratios: R² = 0.79 (n=8) Dataset: ➡️ 4 major GU cancer trials ➡️ 42 predictions ➡️ 3 AI-modeled KM curves ➡️ Claude served as the final judge Where AI got it right: TALAPRO-3 (rPFS, mCSPC) ▶️ AI: HR 0.50 ▶️ Actual: HR 0.48 TALAPRO-3 (OS, mCSPC) ▶️ AI: HR 0.76 ▶️ Actual: HR 0.77 PROTEUS (EFS, Localized Prostate Cancer) ▶️ AI: HR 0.66 ▶️ Actual: HR 0.71 CHIPRO (ORR, Platinum-Resistant Ovarian Cancer) ▶️ AI: ~41% ▶️ Actual: 35.5% Where AI underestimated benefit: CHIPRO (PFS) ▶️ AI: HR 0.70 ▶️ Actual: HR 0.43 RAMPART (DFS, Renal Cancer) ▶️ AI: HR 0.84 ▶️ Actual: HR 0.74 Where AI overestimated outcomes: PROTEUS (MFS) ▶️ AI: HR 0.64 ▶️ Actual: HR 0.80 PROTEUS (pCR) ▶️ AI: ~25% ▶️ Actual: 8.9% CHIPRO (OS) ▶️ AI: HR 0.83 ▶️ Actual: HR 0.93 Key takeaways: ✅ AI performed best on prostate cancer survival endpoints ✅ Directionality was highly accurate for TALAPRO-3 and PROTEUS ✅ The largest miss came in CHIPRO, where AI correctly predicted a positive PFS result but underestimated the magnitude of benefit ✅ AI was generally better at predicting trial success than estimating the size of treatment effect What stood out to you most from the ASCO 2026 GU data? Which result diverged most from expectations? Explore more insights and conference data from #ASCO26 👉 clin.larvol.com/conference/a… #LARVOL #ASCO2026 #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #ClinicalOncology #GUCancer #GenitourinaryCancer #GUCSM #OvarianCancer #RenalCancer #KidneyCancer #ProstateCancer | @DrChoueiri | @DrYukselUrun | @montypal | @TiansterZhang | @UroDocAsh

Most active cancer institutes in 𝕏 during @ASCO 2026. Ranked by views of oncologist posts on clinical trials. Explore more insights and conference data from #ASCO26 👉 clin.larvol.com/conference/a… #LARVOL #ASCO2026 #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #ClinicalOncology #LungCancer #SCLC #esSCLC #NSCLC #LCSM #BreastCancer #TNBC #BCSM #GUCancer #GUCSM #GenitourinaryCancer #KidneyCancer #BladderCancer #ProstateCancer #GICancer #GastrointestinalCancer #GICSM #ColorectalCancer #GastricCancer #LiverCancer #PancreaticCancer #Hematology #Leukemia #Lymphoma #MultipleMyeloma #BloodCancer #HemeOnc #MMSM #LEUSM #LYMSM | @RenovaHospitals | @DanaFarber | @Intermountain | @AnkaraUni | @UTMDAnderson | @juntendo_univ | @NorthwellHealth | @fortis_hospital | @ONealCancerUAB | @Georgetown | @univmiami | @ClevelandClinic | @BCCancer | @UHhospitals | @InstitutoRoffo | @NHSBartsHealth | @UTSWMedCenter | @UIHealth | @DrRishabhOnco | @PTarantinoMD | @DrChoueiri | @marklewismd | @Dave_Gill_SLC | @HHorinouchi | @shimoi_oncology | @AndreaNecchi | @BianchiniGP | @DrYukselUrun | @DrMirallas | @DrBarbiOnc | @Erman_Akkus | @lungoncdoc | @M_Torasawa | @GIMedOnc | @SuyogCancer | @ADesaiMD | @StephenVLiu | @coffman_kelley | @Latinamd | @AmandaNizamMD | @GlopesMd | @dr_yakupergun | @jamecancerdoc | @ronanhsieh | @GillSharlene | @DrSpratticus | @MamMa_mimumemo

Top trending women GU cancer oncologists on 𝕏 during @ASCO 2026. Ranked by views of oncologist posts on clinical trials. Explore more insights and conference data from #ASCO26 👉 clin.larvol.com/conference/a… #LARVOL #ASCO2026 #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #ClinicalOncology #GUCancer #GUCSM #GenitourinaryCancer #KidneyCancer #BladderCancer #ProstateCancer | @nataliagandur | @DrKarineTawagi | @katy_beckermann | @AmandaNizamMD | @shilpaonc | @QianJanieQin | @TiansterZhang | @scocmem | @LauraBukavinaMD | @mjuanfi81

Reactions on top trending GU Cancer trials during @ASCO 2026, curated by @Larvol CLIN. Explore more insights and conference data from #ASCO26 👉 clin.larvol.com/conference/a… #LARVOL #ASCO2026 #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #ClinicalOncology #GUCancer #GUCSM #GenitourinaryCancer #KidneyCancer #BladderCancer #ProstateCancer | @AndreaNecchi | @DrChoueiri | @yekeduz_emre | @DrSpratticus | @nataliagandur | @DrYukselUrun | @tompowles1 | @DrKarineTawagi | @katy_beckermann | @neerajaiims

Top trending companies on X from @ASCO 2026 for GU Cancer, curated by @LARVOL CLIN. Explore more insights and conference data from #ASCO26 👉 clin.larvol.com/conference/a… #LARVOL #ASCO2026 #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #ClinicalOncology #GUCancer #GUCSM #GenitourinaryCancer #KidneyCancer #BladderCancer #ProstateCancer | @AndreaNecchi | @DrChoueiri | @yekeduz_emre | @DrSpratticus | @nataliagandur | @DrYukselUrun | @tompowles1 | @DrKarineTawagi | @katy_beckermann | @neerajaiims

Top trending GU cancer oncologists on 𝕏 during @ASCO 2026. Ranked by views of oncologist posts on clinical trials. Explore more insights and conference data from #ASCO26 👉 clin.larvol.com/conference/a… #LARVOL #ASCO2026 #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #ClinicalOncology #GUCancer #GUCSM #GenitourinaryCancer #KidneyCancer #BladderCancer #ProstateCancer | @AndreaNecchi | @DrChoueiri | @yekeduz_emre | @DrSpratticus | @nataliagandur | @DrYukselUrun | @tompowles1 | @DrKarineTawagi | @katy_beckermann | @neerajaiims

Top trending GU cancer trials on 𝕏 and key results from @ASCO 2026. Ranked by views of oncologist posts on clinical trials. Explore more insights and conference data from #ASCO26 👉 clin.larvol.com/conference/a… #LARVOL #ASCO2026 #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #ClinicalOncology #GUCancer #GUCSM #GenitourinaryCancer #KidneyCancer #BladderCancer #ProstateCancer | @AndreaNecchi | @DrChoueiri | @yekeduz_emre | @DrSpratticus | @nataliagandur | @DrYukselUrun | @tompowles1 | @DrKarineTawagi | @katy_beckermann | @neerajaiims

From bladder cancer to prostate and kidney cancer, several GU oncology studies are already generating strong attention ahead of @ASCO 2026. To identify the trials most likely to shape discussions at the meeting, we asked leading AI models to rank the most anticipated GU cancer readouts. There was particularly strong consensus around EV-302, PROTEUS, RAMPART, and TALAPRO-3 highlighting continued momentum for ADCs, radioligand therapy, immunotherapy combinations, and intensified hormonal strategies across GU cancers. The list underscores key themes shaping the field: ▶️ Expansion of ADC and immunotherapy combinations in urothelial cancer ▶️ Continued evolution of AR-targeted and PARP-based approaches in prostate cancer ▶️ Growing momentum for radioligand and PSMA-targeted therapies ▶️ Increased focus on treatment optimization and de-escalation strategies ▶️ Novel approaches in RCC, NMIBC, and metastatic hormone-sensitive disease Notable studies include: • EV-302 evaluating enfortumab vedotin pembrolizumab in metastatic urothelial cancer • PROTEUS assessing apalutamide intensification in high-risk localized prostate cancer • TALAPRO-3 advancing talazoparib-based combinations in HRR-altered mCSPC • PSMAddition exploring 177Lu-PSMA-617 in PSMA-positive mHSPC • RAMPART evaluating adjuvant durvalumab strategies in renal cell carcinoma Together, these studies reflect how GU oncology continues to move toward more biomarker-driven, targeted, and combination-focused treatment strategies heading into ASCO 2026. Which GU cancer trial are you watching most closely? Explore more insights and conference data from #ASCO26 👉 clin.larvol.com/conference/a… #LARVOL #ASCO2026 #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #ClinicalOncology #GUOncology #GUCancer #GUCSM #GenitourinaryCancer | @DrChoueiri | @neerajaiims | @AndreaNecchi | @UroDocAsh | @nataliagandur

Which #GUCancer abstract are you watching at @ASCO 2026? With ASCO 2026 approaching, oncologists are sharing, discussing, and debating the most anticipated abstracts ahead of the meeting. We’re tracking these conversations in real time, analyzing what’s gaining traction across the global oncology community. Here are the top pre-conference GU cancer abstracts for ASCO 2026. Comment “ASCO GU Trials” below to get the full document, including links. Special thanks to Dr. Mike Thompson, (@mtmdphd) for the original idea. Explore more insights and conference data from #ACSO26 👉clin.larvol.com/conference/a… #LARVOL #ASCO2026 #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #ClinicalOncology #GenitourinaryCancer #GUCSM | @AmandaNizamMD | @yekeduz_emre | @DrKarineTawagi | @katy_beckermann | @nataliagandur

Ahead of @ASCO 2026, we asked leading AI models to forecast outcomes for key GU Cancer trials before the data drops. We analyzed 4 major GU cancer trials, generating 42 predictions across survival and response endpoints, along with 8 AI-modeled Kaplan–Meier curves to visualize how outcomes may separate over time. Each forecast includes hazard ratios, statistical significance (p < 0.05: Yes/No), median survival estimates, ORR, and duration of response projections across settings. Highlights: Strong AR pathway intensification signals in prostate cancer TALAPRO-3 (mCRPC) Talazoparib enzalutamide shows one of the strongest consensus efficacy signals across GU trials ▶️ AI consensus rPFS HR: 0.51 ▶️ Median rPFS: ~35.6 vs 19.3 months ▶️ OS improvement trends positive but remains less certain PROTEUS (Localized prostate cancer) Apalutamide ADT demonstrates consistent benefit across metastasis-free and event-free survival endpoints ▶️ AI consensus MFS HR: 0.65 ▶️ AI consensus EFS HR: 0.65 ▶️ pCR: ~19% Renal cancer: modest directional improvement RAMPART (Renal) Adjuvant durvalumab trends toward DFS improvement, though significance remains inconsistent across models ▶️ AI consensus DFS HR: 0.84 ▶️ OS separation appears limited in current projections Ovarian cancer: clearer PFS than OS signal CHIPRO (Ovarian) Chiauranib paclitaxel shows consistent PFS benefit projections ▶️ AI consensus PFS HR: 0.70 ▶️ Median PFS: ~6.6 vs 4.6 months ▶️ OS significance remains uncertain across models ▶️ ORR: ~35% Across trials, the AI consensus points to continued momentum for AR-targeted intensification strategies in prostate cancer, more modest expectations for adjuvant immunotherapy in renal cancer, and clearer PFS than OS differentiation in ovarian cancer. Which ASCO 2026 GU readouts do you think will surprise and where will AI get it directionally right? Explore more insights and conference data from #ASCO26 👉 clin.larvol.com/conference/a… #LARVOL #ASCO2026 #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #ClinicalOncology #GUCancer #GenitourinaryCancer #GUCSM #OvarianCancer #RenalCancer #KidneyCancer #ProstateCancer | @DrChoueiri | @DrYukselUrun | @montypal | @TiansterZhang | @UroDocAsh

FDA approves atezolizumab for adjuvant treatment of muscle invasive bladder cancer in patients with molecular residual disease fda.gov/drugs/resources-info… Learn more 👉 clin.larvol.com/trial-detail… #LARVOL #CancerResearch #CancerData #OncologyInsights #ClinicalTrial #FDA #FDAApproval #MIBC #BladderCancer #GUCSM #MolecularResidualDisease #MRD | @tompowles1 | @OncoBellmunt | @DrChoueiri | @PGrivasMDPhD | @DrYukselUrun

Here are the 2026 key conferences in #GUCancer. Explore more about oncology conferences, top trials, and reactions from oncologists: clin.larvol.com #LARVOL #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #GenitourinaryCancer #GUCancerResearch #GUCSM #ProstateCancer #UrologicalCancer #KindeyCancer #IPCU36 #GU26 #EAU26 #IKCS26 #AACR26 #AUA26 #ASCO26 #KCRS26 #ESMO26 #SITC26 #EMUC26 #SUO26 The Conferences: @ASCO | @Uroweb | @AACR | @AmerUrological | @kidneycan | @myESMO | @sitcancer | @KidneyCancer | @UroOnc

Top #GUCancer Oncologists of April 2026, curated by @Larvol CLIN based on most viewed 𝕏 posts. Explore more about oncology conferences, top trials, and reactions from oncologists: clin.larvol.com #LARVOL #Oncology #CancerResearch #CancerData #OncologyInsights #ClinicalTrials #GenitourinaryCancer #GUCSM | @AndreaNecchi | @DrChoueiri | @DrYukselUrun | @tompowles1 | @nataliagandur | @katy_beckermann | @scocmem | @drenriquegrande | @Adam_Weiner535 | @PavlosMsaouel

Top #GUCancer Trials of April 2026, curated by @Larvol CLIN based on most viewed 𝕏 posts. Explore more about oncology conferences, top trials, and reactions from oncologists: clin.larvol.com #LARVOL #Oncology #CancerResearch #CancerData #OncologyInsights #ClinicalTrials #GenitourinaryCancer #GUCSM | @AndreaNecchi | @DrChoueiri | @DrYukselUrun | @tompowles1 | @nataliagandur | @katy_beckermann | @scocmem | @drenriquegrande | @Adam_Weiner535 | @PavlosMsaouel

Stay informed about key cancer awareness dates in 2026. Our calendar includes all awareness months and important dates to remember. Explore more about oncology conferences, top trials, and reactions from oncologists: clin.larvol.com #LARVOL #Oncology #CancerCare #CancerAwarenes #BreastCancer #BCSM #LungCancer #LCSM #GICancer #GICSM #GUCancer #GUCSM #Melanoma #Lymphoma #Leukemia #MultipleMyeloma #HEMSM #MMSM #LEUSM #LYMSM #HeadAndNeckCancer #KindneyCancer #ColorectalCancer #BloodCancer

Pt 2. Non ccRCC Rx •papillary Bev/erlo, Cabo, suni •Collecting Duct - platinums •Chromophobe, TFE3 - everolimus 🆕Emerging therapies - I Dxd, VEGFR3, CDK4/6, TIL, CARP1 ⚠️Rx toxicity - TKIs & IO spectrum - Mucositis/Thyroid issues universal #gucsm #rcc #onctwitter

We asked leading AI models to simulate oncologist poll responses before the actual results were announced and compared their predictions to the original poll by @TwoOncDocs ( Dr. @SamArmstrongMD & Dr. @DrKarineTawagi) on Urothelial Carcinoma 👉 x.com/TwoOncDocs/status/2048… Across models, the AI consensus strongly favored bladder-preserving chemoradiation, with: ▶️ TURBT → 5FU/MMC RT (66%) ▶️ TURBT → Gem/cis RT (26%) Clinicians showed a more distributed approach: ▶️ TURBT → 5FU/MMC RT (40.0%) ▶️ TURBT → Gem/cis RT (30.0%) ▶️ EVP → cystectomy (20.0%) Both AI and oncologists aligned on bladder-preserving chemoradiation as the leading strategy, supported by BC2001 data and established radiosensitization approaches. AI placed greater confidence in 5FU/MMC-based regimens, reflecting strong trial evidence and standard-of-care positioning. Oncologists, however, demonstrated more openness to emerging EVP-based strategies, even in a bladder preservation context—highlighting a willingness to incorporate evolving data into real-world decision-making. AI captured the backbone of evidence-based care, but underestimated clinical appetite for newer, less-established approaches. Which approach would you choose in this scenario? #LARVOL #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #UrothelialCarcinoma #BladderCancer #GUCSM | @DrChoueiri | @DrYukselUrun | @tompowles1 | @montypal | @PGrivasMDPhD | @neerajaiims

Efficacy of Immune Checkpoint Blockade in Advanced Upper Tract Urothelial Cancer With DNA Mismatch Repair Deficiency or Microsatellite Instability. Read the full article. bit.ly/4tTV3tW #gucsm